Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
INFECTED COHORT -- ADULTS WITH SUSPECTED SARS-COV-2 INFECTION --
An adult qualifies as having suspected SARS-CoV-2 infection if meeting criteria a, b or c
below:
1. Patients who meet the following clinical criteria plus one of the epidemiological
criteria:
Clinical Criteria: Acute onset of fever and cough OR acute onset of any three of more
of the following signs or symptoms: fever, cough, general weakness /fatigue, headache,
myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered
mental status.
Epidemiological Criteria:
1. Residing or working in an area with a high risk of transmission of virus: closed
residential settings, humanitarian settings such as camp and camp-like settings
for displaced persons; anytime within the 14 days before symptom onset; or
2. Residing or travel to an area with community transmission anytime within the 14
days before symptom onset; or
3. Working in any health care setting, including within health facilities or within
the community; anytime within the 14 days before symptom onset.
2. A patient with severe acute respiratory illness: (acute respiratory infection with
history of fever or measured fever of ≥38C°; and cough; with onset within the last 10
days; and requires hospitalization).
3. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2
Antigen-RDT.
ADULTS WITH PROBABLE SARS-COV-2 INFECTION --
An adult qualifies as having probable SARS-CoV-2 infection if meeting any one of a-d below:
1. A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a
probable or confirmed case or linked to a COVID-19 cluster;
2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease;
3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in
the absence of any other identified cause;
4. Death, not otherwise explained, in an adult with respiratory distress preceding death
AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster
ADULTS WITH CONFIRMED SARS-COV-2 INFECTION --
An adult qualifies as having confirmed SARS-CoV-2 infection if meeting any one of a-d
below:
1. Any person with a positive Nucleic Acid Amplification Test (NAAT);
2. Any person with a positive SARS-CoV-2 Antigen-RDT OR positive SARS-CoV-2 antibody
test* AND meeting either the probable case definition or suspect criteria A OR B;
3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a
probable or confirmed case
4. Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive
SARS-CoV-2 spike protein antibody test IF not vaccinated
- (*)This protocol modifies the WHO criterion b to add detectable SARS-CoV-2
antibody as a qualifying test.
UNINFECTED COHORT -- ADULTS WITH NO SARS-COV-2 INFECTION --
- Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2
infection, AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen in the past,
if being enrolled as a post-acute control (see XII.H), AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen at the time
of enrollment/screening, AND
- Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody
test (spike only if not vaccinated) at the time of enrollment, AND
- Live in the same communities or recruited from the same sources as those in the
SARS-CoV-2 infected cohort, AND
- Note: uninfected individuals may participate independent of their vaccination status
Exclusion Criteria:
- Individuals who have not yet reached the age of majority
- Unable to provide consent
- Individuals in hospice care
- Any serious medical condition which would prevent long-term participation
- Individuals participating in the study NIH RECOVER-Pediatric: Understanding the
long-term impact of COVID on children and families
- Incarcerated individuals
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
INFECTED COHORT -- ADULTS WITH SUSPECTED SARS-COV-2 INFECTION --
An adult qualifies as having suspected SARS-CoV-2 infection if meeting criteria a, b or c
below:
1. Patients who meet the following clinical criteria plus one of the epidemiological
criteria:
Clinical Criteria: Acute onset of fever and cough OR acute onset of any three of more
of the following signs or symptoms: fever, cough, general weakness /fatigue, headache,
myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered
mental status.
Epidemiological Criteria:
1. Residing or working in an area with a high risk of transmission of virus: closed
residential settings, humanitarian settings such as camp and camp-like settings
for displaced persons; anytime within the 14 days before symptom onset; or
2. Residing or travel to an area with community transmission anytime within the 14
days before symptom onset; or
3. Working in any health care setting, including within health facilities or within
the community; anytime within the 14 days before symptom onset.
2. A patient with severe acute respiratory illness: (acute respiratory infection with
history of fever or measured fever of ≥38C°; and cough; with onset within the last 10
days; and requires hospitalization).
3. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2
Antigen-RDT.
ADULTS WITH PROBABLE SARS-COV-2 INFECTION --
An adult qualifies as having probable SARS-CoV-2 infection if meeting any one of a-d below:
1. A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a
probable or confirmed case or linked to a COVID-19 cluster;
2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease;
3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in
the absence of any other identified cause;
4. Death, not otherwise explained, in an adult with respiratory distress preceding death
AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster
ADULTS WITH CONFIRMED SARS-COV-2 INFECTION --
An adult qualifies as having confirmed SARS-CoV-2 infection if meeting any one of a-d
below:
1. Any person with a positive Nucleic Acid Amplification Test (NAAT);
2. Any person with a positive SARS-CoV-2 Antigen-RDT OR positive SARS-CoV-2 antibody
test* AND meeting either the probable case definition or suspect criteria A OR B;
3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a
probable or confirmed case
4. Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive
SARS-CoV-2 spike protein antibody test IF not vaccinated
- (*)This protocol modifies the WHO criterion b to add detectable SARS-CoV-2
antibody as a qualifying test.
UNINFECTED COHORT -- ADULTS WITH NO SARS-COV-2 INFECTION --
- Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2
infection, AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen in the past,
if being enrolled as a post-acute control (see XII.H), AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen at the time
of enrollment/screening, AND
- Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody
test (spike only if not vaccinated) at the time of enrollment, AND
- Live in the same communities or recruited from the same sources as those in the
SARS-CoV-2 infected cohort, AND
- Note: uninfected individuals may participate independent of their vaccination status
Exclusion Criteria:
- Individuals who have not yet reached the age of majority
- Unable to provide consent
- Individuals in hospice care
- Any serious medical condition which would prevent long-term participation
- Individuals participating in the study NIH RECOVER-Pediatric: Understanding the
long-term impact of COVID on children and families
- Incarcerated individuals
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
INFECTED COHORT -- ADULTS WITH SUSPECTED SARS-COV-2 INFECTION --
An adult qualifies as having suspected SARS-CoV-2 infection if meeting criteria a, b or c
below:
1. Patients who meet the following clinical criteria plus one of the epidemiological
criteria:
Clinical Criteria: Acute onset of fever and cough OR acute onset of any three of more
of the following signs or symptoms: fever, cough, general weakness /fatigue, headache,
myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered
mental status.
Epidemiological Criteria:
1. Residing or working in an area with a high risk of transmission of virus: closed
residential settings, humanitarian settings such as camp and camp-like settings
for displaced persons; anytime within the 14 days before symptom onset; or
2. Residing or travel to an area with community transmission anytime within the 14
days before symptom onset; or
3. Working in any health care setting, including within health facilities or within
the community; anytime within the 14 days before symptom onset.
2. A patient with severe acute respiratory illness: (acute respiratory infection with
history of fever or measured fever of ≥38C°; and cough; with onset within the last 10
days; and requires hospitalization).
3. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2
Antigen-RDT.
ADULTS WITH PROBABLE SARS-COV-2 INFECTION --
An adult qualifies as having probable SARS-CoV-2 infection if meeting any one of a-d below:
1. A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a
probable or confirmed case or linked to a COVID-19 cluster;
2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease;
3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in
the absence of any other identified cause;
4. Death, not otherwise explained, in an adult with respiratory distress preceding death
AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster
ADULTS WITH CONFIRMED SARS-COV-2 INFECTION --
An adult qualifies as having confirmed SARS-CoV-2 infection if meeting any one of a-d
below:
1. Any person with a positive Nucleic Acid Amplification Test (NAAT);
2. Any person with a positive SARS-CoV-2 Antigen-RDT OR positive SARS-CoV-2 antibody
test* AND meeting either the probable case definition or suspect criteria A OR B;
3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a
probable or confirmed case
4. Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive
SARS-CoV-2 spike protein antibody test IF not vaccinated
- (*)This protocol modifies the WHO criterion b to add detectable SARS-CoV-2
antibody as a qualifying test.
UNINFECTED COHORT -- ADULTS WITH NO SARS-COV-2 INFECTION --
- Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2
infection, AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen in the past,
if being enrolled as a post-acute control (see XII.H), AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen at the time
of enrollment/screening, AND
- Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody
test (spike only if not vaccinated) at the time of enrollment, AND
- Live in the same communities or recruited from the same sources as those in the
SARS-CoV-2 infected cohort, AND
- Note: uninfected individuals may participate independent of their vaccination status
Exclusion Criteria:
- Individuals who have not yet reached the age of majority
- Unable to provide consent
- Individuals in hospice care
- Any serious medical condition which would prevent long-term participation
- Individuals participating in the study NIH RECOVER-Pediatric: Understanding the
long-term impact of COVID on children and families
- Incarcerated individuals
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
INFECTED COHORT -- ADULTS WITH SUSPECTED SARS-COV-2 INFECTION --
An adult qualifies as having suspected SARS-CoV-2 infection if meeting criteria a, b or c
below:
1. Patients who meet the following clinical criteria plus one of the epidemiological
criteria:
Clinical Criteria: Acute onset of fever and cough OR acute onset of any three of more
of the following signs or symptoms: fever, cough, general weakness /fatigue, headache,
myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered
mental status.
Epidemiological Criteria:
1. Residing or working in an area with a high risk of transmission of virus: closed
residential settings, humanitarian settings such as camp and camp-like settings
for displaced persons; anytime within the 14 days before symptom onset; or
2. Residing or travel to an area with community transmission anytime within the 14
days before symptom onset; or
3. Working in any health care setting, including within health facilities or within
the community; anytime within the 14 days before symptom onset.
2. A patient with severe acute respiratory illness: (acute respiratory infection with
history of fever or measured fever of ≥38C°; and cough; with onset within the last 10
days; and requires hospitalization).
3. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2
Antigen-RDT.
ADULTS WITH PROBABLE SARS-COV-2 INFECTION --
An adult qualifies as having probable SARS-CoV-2 infection if meeting any one of a-d below:
1. A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a
probable or confirmed case or linked to a COVID-19 cluster;
2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease;
3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in
the absence of any other identified cause;
4. Death, not otherwise explained, in an adult with respiratory distress preceding death
AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster
ADULTS WITH CONFIRMED SARS-COV-2 INFECTION --
An adult qualifies as having confirmed SARS-CoV-2 infection if meeting any one of a-d
below:
1. Any person with a positive Nucleic Acid Amplification Test (NAAT);
2. Any person with a positive SARS-CoV-2 Antigen-RDT OR positive SARS-CoV-2 antibody
test* AND meeting either the probable case definition or suspect criteria A OR B;
3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a
probable or confirmed case
4. Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive
SARS-CoV-2 spike protein antibody test IF not vaccinated
- (*)This protocol modifies the WHO criterion b to add detectable SARS-CoV-2
antibody as a qualifying test.
UNINFECTED COHORT -- ADULTS WITH NO SARS-COV-2 INFECTION --
- Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2
infection, AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen in the past,
if being enrolled as a post-acute control (see XII.H), AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen at the time
of enrollment/screening, AND
- Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody
test (spike only if not vaccinated) at the time of enrollment, AND
- Live in the same communities or recruited from the same sources as those in the
SARS-CoV-2 infected cohort, AND
- Note: uninfected individuals may participate independent of their vaccination status
Exclusion Criteria:
- Individuals who have not yet reached the age of majority
- Unable to provide consent
- Individuals in hospice care
- Any serious medical condition which would prevent long-term participation
- Individuals participating in the study NIH RECOVER-Pediatric: Understanding the
long-term impact of COVID on children and families
- Incarcerated individuals
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
INFECTED COHORT -- ADULTS WITH SUSPECTED SARS-COV-2 INFECTION --
An adult qualifies as having suspected SARS-CoV-2 infection if meeting criteria a, b or c
below:
1. Patients who meet the following clinical criteria plus one of the epidemiological
criteria:
Clinical Criteria: Acute onset of fever and cough OR acute onset of any three of more
of the following signs or symptoms: fever, cough, general weakness /fatigue, headache,
myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered
mental status.
Epidemiological Criteria:
1. Residing or working in an area with a high risk of transmission of virus: closed
residential settings, humanitarian settings such as camp and camp-like settings
for displaced persons; anytime within the 14 days before symptom onset; or
2. Residing or travel to an area with community transmission anytime within the 14
days before symptom onset; or
3. Working in any health care setting, including within health facilities or within
the community; anytime within the 14 days before symptom onset.
2. A patient with severe acute respiratory illness: (acute respiratory infection with
history of fever or measured fever of ≥38C°; and cough; with onset within the last 10
days; and requires hospitalization).
3. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2
Antigen-RDT.
ADULTS WITH PROBABLE SARS-COV-2 INFECTION --
An adult qualifies as having probable SARS-CoV-2 infection if meeting any one of a-d below:
1. A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a
probable or confirmed case or linked to a COVID-19 cluster;
2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease;
3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in
the absence of any other identified cause;
4. Death, not otherwise explained, in an adult with respiratory distress preceding death
AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster
ADULTS WITH CONFIRMED SARS-COV-2 INFECTION --
An adult qualifies as having confirmed SARS-CoV-2 infection if meeting any one of a-d
below:
1. Any person with a positive Nucleic Acid Amplification Test (NAAT);
2. Any person with a positive SARS-CoV-2 Antigen-RDT OR positive SARS-CoV-2 antibody
test* AND meeting either the probable case definition or suspect criteria A OR B;
3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a
probable or confirmed case
4. Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive
SARS-CoV-2 spike protein antibody test IF not vaccinated
- (*)This protocol modifies the WHO criterion b to add detectable SARS-CoV-2
antibody as a qualifying test.
UNINFECTED COHORT -- ADULTS WITH NO SARS-COV-2 INFECTION --
- Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2
infection, AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen in the past,
if being enrolled as a post-acute control (see XII.H), AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen at the time
of enrollment/screening, AND
- Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody
test (spike only if not vaccinated) at the time of enrollment, AND
- Live in the same communities or recruited from the same sources as those in the
SARS-CoV-2 infected cohort, AND
- Note: uninfected individuals may participate independent of their vaccination status
Exclusion Criteria:
- Individuals who have not yet reached the age of majority
- Unable to provide consent
- Individuals in hospice care
- Any serious medical condition which would prevent long-term participation
- Individuals participating in the study NIH RECOVER-Pediatric: Understanding the
long-term impact of COVID on children and families
- Incarcerated individuals
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
INFECTED COHORT -- ADULTS WITH SUSPECTED SARS-COV-2 INFECTION --
An adult qualifies as having suspected SARS-CoV-2 infection if meeting criteria a, b or c
below:
1. Patients who meet the following clinical criteria plus one of the epidemiological
criteria:
Clinical Criteria: Acute onset of fever and cough OR acute onset of any three of more
of the following signs or symptoms: fever, cough, general weakness /fatigue, headache,
myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered
mental status.
Epidemiological Criteria:
1. Residing or working in an area with a high risk of transmission of virus: closed
residential settings, humanitarian settings such as camp and camp-like settings
for displaced persons; anytime within the 14 days before symptom onset; or
2. Residing or travel to an area with community transmission anytime within the 14
days before symptom onset; or
3. Working in any health care setting, including within health facilities or within
the community; anytime within the 14 days before symptom onset.
2. A patient with severe acute respiratory illness: (acute respiratory infection with
history of fever or measured fever of ≥38C°; and cough; with onset within the last 10
days; and requires hospitalization).
3. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2
Antigen-RDT.
ADULTS WITH PROBABLE SARS-COV-2 INFECTION --
An adult qualifies as having probable SARS-CoV-2 infection if meeting any one of a-d below:
1. A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a
probable or confirmed case or linked to a COVID-19 cluster;
2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease;
3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in
the absence of any other identified cause;
4. Death, not otherwise explained, in an adult with respiratory distress preceding death
AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster
ADULTS WITH CONFIRMED SARS-COV-2 INFECTION --
An adult qualifies as having confirmed SARS-CoV-2 infection if meeting any one of a-d
below:
1. Any person with a positive Nucleic Acid Amplification Test (NAAT);
2. Any person with a positive SARS-CoV-2 Antigen-RDT OR positive SARS-CoV-2 antibody
test* AND meeting either the probable case definition or suspect criteria A OR B;
3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a
probable or confirmed case
4. Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive
SARS-CoV-2 spike protein antibody test IF not vaccinated
- (*)This protocol modifies the WHO criterion b to add detectable SARS-CoV-2
antibody as a qualifying test.
UNINFECTED COHORT -- ADULTS WITH NO SARS-COV-2 INFECTION --
- Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2
infection, AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen in the past,
if being enrolled as a post-acute control (see XII.H), AND
- Has a documented negative SARS-CoV-2 PCR test from a respiratory specimen at the time
of enrollment/screening, AND
- Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody
test (spike only if not vaccinated) at the time of enrollment, AND
- Live in the same communities or recruited from the same sources as those in the
SARS-CoV-2 infected cohort, AND
- Note: uninfected individuals may participate independent of their vaccination status
Exclusion Criteria:
- Individuals who have not yet reached the age of majority
- Unable to provide consent
- Individuals in hospice care
- Any serious medical condition which would prevent long-term participation
- Individuals participating in the study NIH RECOVER-Pediatric: Understanding the
long-term impact of COVID on children and families
- Incarcerated individuals
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting